3 Biotech

, 8:414 | Cite as

Cloning and expression of truncated ORF2 as a vaccine candidate against hepatitis E virus

  • Dibya Rani
  • Rahul Saxena
  • Baibaswata Nayak
  • Sudha SrivastavaEmail author
Short Reports


Hepatitis E virus infection is responsible for acute viral hepatitis and associated with high mortality and still birth in pregnant women in developing countries. We report expression of truncated forms of HEV ORF2 as potential vaccine candidates for nanoparticle-based delivery. These two truncated ORF2 proteins (54 kDa and 26 kDa) have been reported to be highly immunogenic and can be used as nanoparticle-based vaccine candidate. The bacterial expressed protein was purified by affinity chromatography and further confirmed by western blot using anti-HEV antibody. The chitosan nanoemulsion was synthesized using ultrasonic waves. The nanoparticle size was found to be 120–160 nm and the entrapment efficiency of purified truncated ORF2 proteins within these nanoparticles was 70% (26 kDa) and 59% (54 kDa). In cell cytotoxicity analysis, 100 µg/mL nanoemulsion was found suitable for cell viability in both HeLa and THP1 cell lines. Release kinetics of encapsulated proteins at physiological pH 7.4 showed 26–59% and 9.7–40% release of 26 kDa and 54 kDa protein within 1 h that gradually increased with time (48 h). Encapsulated proteins were found to be unstable at pH 1.2.


Chitosan Nanoemulsion Hepatitis E virus Truncated ORF2 



Authors SS, DR and RS are thankful to Jaypee Institute of Information Technology and BN is thankful to AIIMS for the support for carrying out research work. DR and RS are also thankful to DST-INSPIRE (IF 150454 and IF 150897), Government of India for the fellowship and contingency Grant.

Compliance with ethical standards

Conflict of interest

All authors hereby declare that there is no conflict of interest.


  1. Akbuǧa J, Durmaz G (1994) Preparation and evaluation of cross-linked chitosan microspheres containing furosemide. Int J Pharm. CrossRefGoogle Scholar
  2. Arankalle VA, Lole KS, Deshmukh TM et al (2009) Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes. Vaccine. CrossRefPubMedGoogle Scholar
  3. Huang WJ, Zhang HY, Harrison TJ et al (2009) Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4. Arch Virol. CrossRefPubMedPubMedCentralGoogle Scholar
  4. Jesus S, Soares E, Borchard G, Borges O (2017) Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. Nanomedicine. CrossRefPubMedGoogle Scholar
  5. Khuroo MS, Teli MR, Skidmore S et al (1981) Incidence and severity of viral hepatitis in pregnancy. Am J Med. CrossRefPubMedGoogle Scholar
  6. Li TC, Yamakawa Y, Suzuki K et al (1997) Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71(10):7207–7213PubMedPubMedCentralGoogle Scholar
  7. Li TC, Suzaki Y, Ami Y et al (2004) Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant Hepatitis E virus-like particles. Vaccine. CrossRefPubMedGoogle Scholar
  8. Li SW, Zhang J, Li YM et al (2005) A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine. CrossRefPubMedGoogle Scholar
  9. van Meerloo J, Kaspers GJL, Cloos J (2011) Cell sensitivity assay: the MTT assay. In: Cree I (ed) Cancer cell culture: methods and protocols. Methods in molecular biology, vol 731. Humana Press, Totowa, pp 237–245. CrossRefGoogle Scholar
  10. Nair VP, Anang S, Subramani C et al (2016) Endoplasmic reticulum stress induced synthesis of a novel Viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Purcell RH, Nguyen H, Shapiro M et al (2003) Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine. CrossRefPubMedGoogle Scholar
  12. Purdy MA, McCaustland KA, Krawczynski K et al (1992) Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recognized by antibodies in sera from human cases and experimentally infected primates. Arch Virol 123:335–349CrossRefGoogle Scholar
  13. Rein DB, Stevens GA, Theaker J et al (2012) The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. CrossRefPubMedGoogle Scholar
  14. Taherkhani R, Farshadpour F (2015) A new strategy for development of hepatitis E vaccine: epitope-based vaccines. Pathog Infect Dis. CrossRefGoogle Scholar
  15. Tam AW, Smith MM, Guerra ME et al (1991) Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology. CrossRefPubMedGoogle Scholar
  16. Yamashita T, Mori Y, Miyazaki N et al (2009) Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci USA. CrossRefPubMedGoogle Scholar
  17. Zhang M, Emerson SU, Nguyen H et al (2001) Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells. Vaccine. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of BiotechnologyJaypee Institute of Information TechnologyNoidaIndia
  2. 2.Department of GastroenterologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations